JAK1 and infection: This was particularly apparent in experiments using the JAK1/2 inhibitor ruxolitinib, which potently reduced the ISG response to viruses with defective viral capsids, but had no impact on infection read out by GFP positivity of the cells (Figs EV2C and EV4E, and EV5A).